A Prospective, Non-Interventional Cohort Study of Approved Sofosbuvir-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice
Phase of Trial: Phase IV
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 10 Jun 2017 Biomarkers information updated
- 10 Apr 2017 Planned End Date changed from 1 Mar 2019 to 1 Jan 2019.
- 10 Apr 2017 Planned primary completion date changed from 1 Mar 2019 to 1 Jan 2019.